search
Back to results

SEAM Trial: Sutureless End to End Anastomosis by Magnetic Compression (SEAM)

Primary Purpose

Retraction of Ileostomy

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Ileostomy Reversal using Self Forming Magnets (SFM)
Sponsored by
GI Windows, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Retraction of Ileostomy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Participants must be >18 years
  2. Participant has a temporary loop ileostomy that was created ≥ 2 months but ≤ 10 months prior to reversal. NOTE: The inclusion of patients with ileostomy after total colectomy and palliative ileostomy is permitted if the patients have estimated overall survival of greater than 2 years or if the loop ileostomy is resulting in persistent fluid and electrolyte disorders or other significant stoma related complications where closure of the ileostomy is required for patient safety.
  3. Preoperative clearance with confirmation of anastomotic integrity of the original resection; i.e., absence of active exacerbation of inflammatory disease (as applicable), stricture or leakage at or distal to the diverted colorectal anastomosis via gastrografin enema and/or endoscopy based on physician's discretion
  4. BMI ≤ 40 kg/m2
  5. American Society of Anesthesiologist (ASA) score < IV at time of reversal
  6. All cancer patients must have completed chemotherapy ≥2 months prior to ileostomy closure
  7. Subject or authorized representative have been informed of the nature of the study and has provided written informed consent approved by the appropriate local Institutional Review Board (IRB) and agrees to comply with all protocol-specified follow-up appointments

Exclusion Criteria:

  1. Radiological or clinical signs of anastomosis leak, active infection (except uncomplicated urinary tract infection)
  2. Ongoing or prolonged ileus or bowel obstruction from original surgery
  3. Requires/d additional abdominal surgery (e.g., Major hernia repair, either necessitating mesh and/or abdominal wall reconstruction) after ileostomy or requires/d concurrent abdominal surgery during reversal procedure
  4. Multiple small bowel obstructions occurring between ileostomy creation and closure requiring a formal abdominal exploration through a midline incision at the time of ileostomy closure or any other participant in whom laparotomy is required at time of ileostomy closure
  5. Requires/d laparotomy at time of ileostomy closure
  6. Congestive heart failure with ejection fraction<35% or clinically significant arrhythmia (any rhythm disturbances except sinus tachycardia, sinus bradycardia or a sinus rhythm with premature atrial or ventricular complexes)
  7. Decompensated chronic obstructive lung disease
  8. Pulmonary embolism or myocardial infarction in the prior 6 months
  9. Congenital or acquired anomalies of the gastrointestinal tract, including atresias, stenosis, luminal distortion or malrotation
  10. Coagulation deficiency not normalized by medical treatment or platelet count <50,000/µL at time of reversal
  11. Known moderate to severe renal disease (eGFR < 44 milliliters per minute per 1.73m2) or ongoing dialysis

Sites / Locations

  • Advent HealthRecruiting
  • Colon and Rectal Clinical of OrlandoRecruiting
  • Beth Israel Deaconess Medical CenterRecruiting
  • University of Massachusetts Medical SchoolRecruiting
  • Spectrum Health / Ferguson ClinicRecruiting
  • Trinity Health Michigan Heart
  • Dartmouth Hitchcock Medical CenterRecruiting
  • The Mount Sinai Medical CenterRecruiting
  • St Francis HospitalRecruiting
  • Novant Health Clinical ResearchRecruiting
  • Penn State Milton S. Hershey Medical CenterRecruiting
  • Vanderbilt University Medical CenterRecruiting
  • UT Health Science Center at HoustonRecruiting
  • The Medical College of WisconsinRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Prospective Evaluation of the SFM Device

Retrospective Chart Review of Historical Controls

Arm Description

This is a multicenter, single-arm study in which clinical outcomes prospectively evaluated for a minimum of 100 subjects undergoing ileostomy reversal using the SFM Anastomosis Device

In order to have a sufficient pool of retrospective patients for matching, retrospective data will be collected for a minimum of 300 patients. The historical control cohort will be accrued from the same pool of institutions participating in the prospective study.

Outcomes

Primary Outcome Measures

Achieving anastomosis success
The primary effectiveness hypothesis is that anastomosis success rate for the SFM device will be non-inferior to the anastomosis success rate observed for the propensity-matched historical control group

Secondary Outcome Measures

Full Information

First Posted
September 8, 2021
Last Updated
February 19, 2023
Sponsor
GI Windows, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT05046730
Brief Title
SEAM Trial: Sutureless End to End Anastomosis by Magnetic Compression
Acronym
SEAM
Official Title
SEAM Trial: Sutureless End to End Anastomosis by Magnetic Compression: A Study to Evaluate Safety and Effectiveness of Self-Forming Magnet (SFM) Anastomosis Device: A Historically Controlled Propensity Matched Study
Study Type
Interventional

2. Study Status

Record Verification Date
October 2022
Overall Recruitment Status
Recruiting
Study Start Date
February 1, 2022 (Actual)
Primary Completion Date
October 1, 2023 (Anticipated)
Study Completion Date
December 30, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
GI Windows, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The objectives of this study are to determine the safety and effectiveness of the SFM Anastomosis Device when used to create a small bowel anastomosis for patients undergoing ileostomy reversal as compared with a propensity-matched historic control group of patients who underwent ileostomy reversal using a conventional closure technique (sutures or stapler).
Detailed Description
This is a multicenter, single-arm study in which clinical outcomes prospectively evaluated for a minimum of 100 subjects undergoing ileostomy reversal using the SFM Anastomosis Device will be 1:1 propensity score matched through nearest neighbor matching to a historical control cohort of patients who underwent ileostomy reversal using conventional closure techniques. In order to have a sufficient pool of retrospective patients for matching, retrospective data will be collected for a minimum of 300 patients. The historical control cohort will be accrued from the same pool of institutions participating in the prospective study. Eligibility criteria will be standardized between the prospective investigational treatment arm and the historical control. Within this analysis, propensity score (PS) matching will be used to reduce bias due to potential differences in key covariates between the prospective and retrospective cohorts.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Retraction of Ileostomy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Factorial Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
400 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Prospective Evaluation of the SFM Device
Arm Type
Experimental
Arm Description
This is a multicenter, single-arm study in which clinical outcomes prospectively evaluated for a minimum of 100 subjects undergoing ileostomy reversal using the SFM Anastomosis Device
Arm Title
Retrospective Chart Review of Historical Controls
Arm Type
Active Comparator
Arm Description
In order to have a sufficient pool of retrospective patients for matching, retrospective data will be collected for a minimum of 300 patients. The historical control cohort will be accrued from the same pool of institutions participating in the prospective study.
Intervention Type
Device
Intervention Name(s)
Ileostomy Reversal using Self Forming Magnets (SFM)
Intervention Description
The magnets will be manually deployed into the small intestine during open surgery following creation of a mini or full laparotomy as clinically indicated. Once the desired segment of small bowel is resected, the magnet is inserted through the open ends of each bowel section. Once proper magnet position is confirmed and the bowel ends are approximated, the magnets couple to form the anastomosis.
Primary Outcome Measure Information:
Title
Achieving anastomosis success
Description
The primary effectiveness hypothesis is that anastomosis success rate for the SFM device will be non-inferior to the anastomosis success rate observed for the propensity-matched historical control group
Time Frame
30 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Participants must be >18 years Participant has a temporary loop ileostomy that was created ≥ 2 months but ≤ 10 months prior to reversal. NOTE: The inclusion of patients with ileostomy after total colectomy and palliative ileostomy is permitted if the patients have estimated overall survival of greater than 2 years or if the loop ileostomy is resulting in persistent fluid and electrolyte disorders or other significant stoma related complications where closure of the ileostomy is required for patient safety. Preoperative clearance with confirmation of anastomotic integrity of the original resection; i.e., absence of active exacerbation of inflammatory disease (as applicable), stricture or leakage at or distal to the diverted colorectal anastomosis via gastrografin enema and/or endoscopy based on physician's discretion BMI ≤ 40 kg/m2 American Society of Anesthesiologist (ASA) score < IV at time of reversal All cancer patients must have completed chemotherapy ≥2 months prior to ileostomy closure Subject or authorized representative have been informed of the nature of the study and has provided written informed consent approved by the appropriate local Institutional Review Board (IRB) and agrees to comply with all protocol-specified follow-up appointments Exclusion Criteria: Radiological or clinical signs of anastomosis leak, active infection (except uncomplicated urinary tract infection) Ongoing or prolonged ileus or bowel obstruction from original surgery Requires/d additional abdominal surgery (e.g., Major hernia repair, either necessitating mesh and/or abdominal wall reconstruction) after ileostomy or requires/d concurrent abdominal surgery during reversal procedure Multiple small bowel obstructions occurring between ileostomy creation and closure requiring a formal abdominal exploration through a midline incision at the time of ileostomy closure or any other participant in whom laparotomy is required at time of ileostomy closure Requires/d laparotomy at time of ileostomy closure Congestive heart failure with ejection fraction<35% or clinically significant arrhythmia (any rhythm disturbances except sinus tachycardia, sinus bradycardia or a sinus rhythm with premature atrial or ventricular complexes) Decompensated chronic obstructive lung disease Pulmonary embolism or myocardial infarction in the prior 6 months Congenital or acquired anomalies of the gastrointestinal tract, including atresias, stenosis, luminal distortion or malrotation Coagulation deficiency not normalized by medical treatment or platelet count <50,000/µL at time of reversal Known moderate to severe renal disease (eGFR < 44 milliliters per minute per 1.73m2) or ongoing dialysis
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Peter J Lukin
Phone
9787610183
Email
peter.lukin@giwindows.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Evangelos Messaris, MD, Ph.D
Organizational Affiliation
Beth Israel Deaconess Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Advent Health
City
Orlando
State/Province
Florida
ZIP/Postal Code
32803
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Diana Paredes, RN
Email
diana.paredes@adventhealth.com
First Name & Middle Initial & Last Name & Degree
Matthew Albert, MD
Facility Name
Colon and Rectal Clinical of Orlando
City
Orlando
State/Province
Florida
ZIP/Postal Code
32806
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nancy Joiner
Email
NJoiner@crcorlando.com
Facility Name
Beth Israel Deaconess Medical Center
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anna George
Email
ageorge5@bidmc.harvard.edu
First Name & Middle Initial & Last Name & Degree
Evangelos Messaris, MD, Ph.D
Facility Name
University of Massachusetts Medical School
City
Worcester
State/Province
Massachusetts
ZIP/Postal Code
01655
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sharon Balcom, RN
Phone
508-334-4918
Email
Sharon.Balcom@umassmed.edu
Facility Name
Spectrum Health / Ferguson Clinic
City
Grand Rapids
State/Province
Michigan
ZIP/Postal Code
49508
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
James W Ogilvie, MD, MS, FACS, FASCRS
Phone
616.267.7100
Email
James.OgilvieJr@spectrumhealth.org
First Name & Middle Initial & Last Name & Degree
James W Ogilvie, MD, MS, FACS, FASCRS
Facility Name
Trinity Health Michigan Heart
City
Ypsilanti
State/Province
Michigan
ZIP/Postal Code
48197
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sarah Whitsett
Email
sarah_whitsett@michiganheart.com
First Name & Middle Initial & Last Name & Degree
Melissa Chang, MD
Facility Name
Dartmouth Hitchcock Medical Center
City
Lebanon
State/Province
New Hampshire
ZIP/Postal Code
03766
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Penny J Doughty
Email
Penny.J.Doughty@hitchcock.org
Facility Name
The Mount Sinai Medical Center
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hannah Son
Phone
212-241-8835
Email
Hannah.Son@mountsinai.org
First Name & Middle Initial & Last Name & Degree
Patricia Sylla, MD
Facility Name
St Francis Hospital
City
Roslyn
State/Province
New York
ZIP/Postal Code
11576
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lyn Santiago, RN, CCRC
Phone
516-562-6763
Email
Lyn.santiago@chsli.org
Facility Name
Novant Health Clinical Research
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27101
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
David Hiller, MD
Email
djhiller@novanthealth.org
Facility Name
Penn State Milton S. Hershey Medical Center
City
Hershey
State/Province
Pennsylvania
ZIP/Postal Code
17033
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michael Deutsch, MD
Email
mdeutsch1@pennstatehealth.psu.edu
Facility Name
Vanderbilt University Medical Center
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37232
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Joan Kaiser
Email
joan.l.kaiser@vumc.org
Facility Name
UT Health Science Center at Houston
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Angielyn Rivera
Email
angielyn.r.rivera@uth.tmc.edu
Facility Name
The Medical College of Wisconsin
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53226
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kathryn Hoffman, MS, CCRP
Phone
414-955-1479
Email
khoffman@mcw.edu

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
No: There is not a plan to make IPD available.

Learn more about this trial

SEAM Trial: Sutureless End to End Anastomosis by Magnetic Compression

We'll reach out to this number within 24 hrs